BioEclipse Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioEclipse Therapeutics, Inc. - overview
Established
2006
Location
San Francisco, CA, US
Primary Industry
Pharmaceuticals
About
BioEclipse Therapeutics, Inc. is a biotechnology company focused on advancing immunotherapy treatments for advanced cancers, particularly targeting resistant and recurrent solid tumors through innovative cell-based therapies. Founded in 2006 and headquartered in San Francisco, US, BioEclipse Therapeutics, Inc. specializes in immunotherapy solutions for cancer.
The company has undertaken four deals, with its most recent funding round occurring on October 10, 2019. The firm secured USD 2. 36 mn in Series A funding from investors including DEFTA Partners and Revelis Capital Group. CEO Pamela Contag leads the company, overseeing its strategic direction in the competitive biotechnology landscape.
BioEclipse Therapeutics™ develops proprietary immunotherapy products aimed at treating advanced cancers, focusing on patients with resistant and recurrent solid tumors. Their key therapies include CRX200, an allogeneic therapy designed for off-the-shelf availability, and CRX100, an autologous therapy currently in Phase 1b clinical trials. Both therapies employ engineered living cells that enhance the immune system's ability to detect and destroy cancer cells, targeting primarily oncologists and healthcare institutions in North America and Europe. BioEclipse Therapeutics™ operates within the biotechnology sector, primarily engaging in B2B transactions with healthcare providers and research institutions that seek innovative solutions for cancer treatment.
Revenue generation is anticipated through partnerships with healthcare facilities and the potential commercial sale of proprietary therapies following successful clinical trials and regulatory approvals. Specific pricing strategies for CRX200 and CRX100 are not disclosed, but they will likely reflect market demands and the competitive landscape in oncology therapeutics. Following its recent Series A funding of USD 2. 36 mn raised on October 10, 2019, BioEclipse Therapeutics, Inc.
plans to enhance its product development and expand its market reach. This includes launching new immunotherapy products and entering new geographic regions, specifically targeting North America and Europe by 2023. The funding will be utilized to support ongoing clinical trials and prepare for future commercialization of its therapies.
Current Investors
DEFTA Partners, TSVC, Plum Alley
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.bioeclipse.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
BioEclipse Therapeutics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.